Briefing
Highly Accurate Detection of Circulating Tumor DNA for Monitoring Minimal Residual Disease in Solid Tumors: Analytical and Clinical Validation of the Haystack MRD Assay.
The paper reports analytical and clinical validation of the Haystack MRD assay for detecting rare ctDNA fragments among cell-free DNA.
- Design: Evidence level 3
- Assay: Haystack
The Journal of Molecular DiagnosticsPubMed 42624249DOI 10.1016/j.jmoldx.2026.07.006